$69.20
At close: Apr 16, 4:00 PM EDT
$69.20
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
ANI Pharmaceuticals Insider Trading Activity | NASDAQ:ANIP | Benzinga
Track the latest ANI Pharmaceuticals insider trading activity. Stay informed on recent buys, sells, and market impact for ANI Pharmaceuticals stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are ANI Pharmaceuticals Inc Insiders Doing?
At ANI Pharmaceuticals Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 2.27K shares worth $148.87K, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On March 14, 2025, Meredith Cook, the company's SR. VP, GENERAL COUNSEL & SEC. sold 400 shares for $63.33 each.
- On April 14, 2025, Meredith Cook, the company's SR. VP, GENERAL COUNSEL & SEC. sold 400 shares for $68.96 each.
- On February 24, 2025, Krista Davis, the company's SVP, CHIEF HR OFFICER sold 1K shares for $60.2 each.
Ownership Statistics for ANI Pharmaceuticals Inc
Shares Outstanding
21.763M
Insider Shares Owned
2.939M
Insider Percentage Owned
13.5%
Institutional Shares Held
10.876M
Institutional Percentage Held
50.4%
| Apr 14, 2025 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $68.96 | -$27.58K | SELL | -0.50% | 80.14K | Apr 14 | View |
| Mar 20, 2025 | Krista Davis | SVP, CHIEF HR OFFICER | -1.87K | $65.00 | -$121.29K | SELL | -2.80% | 64.66K | Mar 19 | View |
| Mar 14, 2025 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $63.33 | -$25.33K | SELL | -0.49% | 80.55K | Mar 13 | View |
| Mar 10, 2025 | Krista Davis | SVP, CHIEF HR OFFICER | -1.00K | $60.86 | -$60.86K | SELL | -1.48% | 66.53K | Mar 07 | View |
| Mar 07, 2025 | Ori Gutwerg | SVP, GENERICS | -5.08K | $45.75 | -$313.60K | SELL | -5.13% | 94.09K | Mar 05 | View |
| Feb 24, 2025 | Krista Davis | SVP, CHIEF HR OFFICER | -1.00K | $60.20 | -$60.20K | SELL | -1.44% | 68.62K | Feb 21 | View |
| Feb 18, 2025 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 26.46K | $59.06 | -$108.31K | GRANT | 47.59% | 82.04K | Feb 12 - Feb 14 | View |
| Jan 13, 2025 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -400.00 | $53.92 | -$21.57K | SELL | -0.71% | 55.59K | Jan 13 | View |
| Dec 18, 2024 | Stephen P Carey | SVP & CFO | -7.50K | $55.79 | -$418.43K | SELL | -4.63% | 154.47K | Dec 17 | View |
| Dec 16, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.24 | -$14.06K | SELL | -0.44% | 55.99K | Dec 13 | View |
| Dec 12, 2024 | Krista Davis | SVP, CHIEF HR OFFICER | -1.00K | $60.00 | -$60.00K | SELL | -2.00% | 49.06K | Dec 11 | View |
| Nov 27, 2024 | Nikhil Lalwani | PRESIDENT & CEO | -3.48K | $43.49 | -$1.07M | SELL | -0.93% | 370.38K | Nov 26 | View |
| Nov 18, 2024 | Christopher Mutz | HEAD OF RARE DISEASE | -6.50K | $57.70 | -$375.05K | SELL | -7.81% | 76.78K | Nov 15 | View |
| Nov 14, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $61.36 | -$15.34K | SELL | -0.44% | 56.24K | Nov 13 | View |
| Oct 15, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $57.19 | -$14.30K | SELL | -0.44% | 56.49K | Oct 14 | View |
| Sep 16, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.82 | -$14.21K | SELL | -0.44% | 56.74K | Sep 13 | View |
| Aug 14, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $59.62 | -$14.90K | SELL | -0.44% | 56.99K | Aug 13 | View |
| Jul 19, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -2.74K | $62.00 | -$170.07K | SELL | -0.43% | 637.62K | Jul 18 | View |
| Jul 17, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -47.26K | $63.73 | -$3.01M | SELL | -6.87% | 640.36K | Jul 15 - Jul 17 | View |
| Jul 15, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $64.91 | -$16.23K | SELL | -0.42% | 58.98K | Jul 12 | View |
| Jul 02, 2024 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $63.44 | -$1.27M | SELL | -7.61% | 242.91K | Jul 01 | View |
| Jun 24, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -20.00K | $58.90 | -$1.18M | SELL | -2.83% | 687.62K | Jun 21 | View |
| Jun 20, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -30.00K | $60.59 | -$1.82M | SELL | -4.07% | 707.62K | Jun 17 - Jun 20 | View |
| Jun 14, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $63.80 | -$15.95K | SELL | -0.42% | 59.23K | Jun 13 | View |
| Jun 06, 2024 | Ori Gutwerg | SVP, GENERICS | -2.98K | $67.00 | -$200.00K | SELL | -3.72% | 77.23K | Jun 05 | View |
| Jun 06, 2024 | Stephen P Carey | SVP & CFO | -5.00K | $63.58 | -$317.90K | SELL | -2.99% | 161.97K | Jun 04 | View |
| Jun 04, 2024 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $64.41 | -$1.29M | SELL | -7.07% | 262.90K | Jun 03 | View |
| May 22, 2024 | Christopher Mutz | HEAD OF RARE DISEASE | -2.00K | $61.61 | -$123.22K | SELL | -2.35% | 83.28K | May 21 | View |
| May 21, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -12.86K | $61.81 | -$794.57K | SELL | -1.71% | 737.62K | May 20 | View |
| May 17, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -37.15K | $64.37 | -$2.39M | SELL | -4.72% | 750.48K | May 15 - May 17 | View |
| May 17, 2024 | Renee P Tannenbaum | DIRECTOR | -2.00K | $63.87 | -$127.74K | SELL | -9.90% | 18.21K | May 16 | View |
| May 16, 2024 | Nikhil Lalwani | PRESIDENT & CEO | -16.67K | $66.10 | -$1.10M | SELL | -4.23% | 377.50K | May 14 | View |
| May 13, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $67.69 | -$16.92K | SELL | -0.42% | 59.48K | May 13 | View |
| May 03, 2024 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $66.62 | -$1.33M | SELL | -6.60% | 282.90K | May 01 | View |
| Apr 22, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -27.23K | $65.10 | -$1.77M | SELL | -3.34% | 787.62K | Apr 18 - Apr 19 | View |
| Apr 17, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -22.77K | $65.91 | -$1.50M | SELL | -2.72% | 814.85K | Apr 15 - Apr 17 | View |
| Apr 15, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $67.79 | -$16.95K | SELL | -0.42% | 59.73K | Apr 12 | View |
| Apr 02, 2024 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $67.25 | -$1.34M | SELL | -6.19% | 302.90K | Apr 01 | View |
| Mar 13, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $66.54 | -$16.64K | SELL | -0.42% | 59.98K | Mar 13 | View |
| Mar 13, 2024 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $65.81 | -$1.32M | SELL | -5.83% | 322.90K | Mar 11 | View |
| Mar 11, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -10.00K | $67.17 | -$671.70K | SELL | -1.18% | 837.62K | Mar 08 | View |
| Mar 11, 2024 | Stephen P Carey | SVP & CFO | -12.00K | $65.96 | -$791.69K | SELL | -6.33% | 177.71K | Mar 07 - Mar 11 | View |
| Mar 08, 2024 | Nikhil Lalwani | PRESIDENT & CEO | -62.32K | $66.27 | -$4.13M | SELL | -13.15% | 411.63K | Mar 06 - Mar 08 | View |
| Mar 07, 2024 | James G Marken | SVP OPS & PROD DEV | -26.37K | $66.40 | -$1.75M | SELL | -17.72% | 122.46K | Mar 07 | View |
| Mar 07, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -40.00K | $65.77 | -$2.63M | SELL | -4.51% | 847.62K | Mar 05 - Mar 07 | View |
| Mar 06, 2024 | Christopher Mutz | HEAD OF RARE DISEASE | -5.00K | $66.00 | -$330.00K | SELL | -5.41% | 87.39K | Mar 05 | View |
| Mar 06, 2024 | Antonio R Pera | DIRECTOR | -7.00K | $65.20 | -$456.40K | SELL | -20.82% | 26.63K | Mar 04 | View |
| Feb 13, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.04 | -$14.01K | SELL | -0.67% | 36.80K | Feb 13 | View |
| Jan 23, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -25.22K | $56.17 | -$1.42M | SELL | -2.76% | 887.62K | Jan 19 - Jan 23 | View |
| Jan 18, 2024 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -24.78K | $55.29 | -$1.37M | SELL | -2.64% | 912.84K | Jan 16 - Jan 18 | View |
| Jan 16, 2024 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $56.43 | -$14.11K | SELL | -0.67% | 37.05K | Jan 12 | View |
| Dec 19, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $52.55 | -$2.63M | SELL | -5.06% | 937.62K | Dec 15 - Dec 19 | View |
| Dec 11, 2023 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $49.21 | -$12.30K | SELL | -0.67% | 37.30K | Dec 11 | View |
| Nov 20, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -13.00K | $51.00 | -$663.00K | SELL | -1.30% | 987.62K | Nov 17 | View |
| Nov 16, 2023 | Krista Davis | SVP, CHIEF HR OFFICER | -2.62K | $53.81 | -$141.09K | SELL | -7.45% | 32.59K | Nov 15 | View |
| Nov 16, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -36.19K | $53.00 | -$1.92M | SELL | -3.49% | 1.00M | Nov 14 - Nov 16 | View |
| Nov 14, 2023 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | -250.00 | $52.03 | -$13.01K | SELL | -0.66% | 37.55K | Nov 13 | View |
| Nov 13, 2023 | Christopher Mutz | HEAD OF RARE DISEASE | -3.00K | $52.47 | -$157.41K | SELL | -4.50% | 63.61K | Nov 10 | View |
| Oct 19, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -25.00K | $57.75 | -$1.44M | SELL | -2.35% | 1.04M | Oct 17 - Oct 19 | View |
| Oct 17, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -25.00K | $57.96 | -$1.45M | SELL | -2.30% | 1.06M | Oct 13 - Oct 16 | View |
| Oct 03, 2023 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $56.48 | -$1.13M | SELL | -5.84% | 322.17K | Oct 02 | View |
| Sep 19, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $61.81 | -$3.09M | SELL | -4.40% | 1.09M | Sep 15 - Sep 19 | View |
| Sep 05, 2023 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $64.70 | -$1.29M | SELL | -5.52% | 342.17K | Sep 01 | View |
| Aug 30, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $63.22 | -$3.16M | SELL | -4.21% | 1.14M | Aug 28 - Aug 29 | View |
| Aug 25, 2023 | Ori Gutwerg | SVP, GENERICS | -2.06K | $46.94 | -$545.67K | SELL | -3.27% | 60.91K | Aug 23 | View |
| Aug 25, 2023 | James G Marken | SVP OPS & PROD DEV | 1.49K | $50.63 | -$40.49K | SELL-OPTIONS | 1.13% | 133.11K | Aug 23 | View |
| Aug 16, 2023 | MERIDIAN VENTURE PARTNERS II LPMeridian Venture Partners II GP LPMeridian Venture Partners II CoRobert E. Brown Jr. | 10% OWNER | -200.00K | $58.50 | -$11.70M | SELL | -9.90% | 1.82M | Aug 16 | View |
| Aug 16, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -50.00K | $61.35 | -$3.07M | SELL | -4.04% | 1.19M | Aug 14 - Aug 15 | View |
| Aug 16, 2023 | Stephen P Carey | SVP & CFO | -17.64K | $61.37 | -$1.08M | SELL | -10.17% | 155.84K | Aug 14 | View |
| Aug 15, 2023 | Antonio R Pera | DIRECTOR | -3.00K | $60.37 | -$181.11K | SELL | -8.19% | 33.63K | Aug 14 | View |
| Aug 15, 2023 | Nikhil Lalwani | PRESIDENT & CEO | -56.67K | $43.66 | -$3.65M | SELL | -13.82% | 353.39K | Aug 11 - Aug 15 | View |
| Aug 03, 2023 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $51.06 | -$1.02M | SELL | -5.23% | 362.17K | Aug 01 | View |
| Jul 21, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -23.47K | $52.02 | -$1.22M | SELL | -1.86% | 1.24M | Jul 19 - Jul 21 | View |
| Jul 18, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -26.53K | $51.02 | -$1.35M | SELL | -2.06% | 1.26M | Jul 14 - Jul 18 | View |
| Jul 06, 2023 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $53.43 | -$1.07M | SELL | -4.97% | 382.17K | Jul 03 | View |
| Jun 23, 2023 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | -20.00K | $51.32 | -$1.03M | SELL | -4.74% | 402.17K | Jun 22 | View |
| Jun 22, 2023 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | -40.00K | $51.75 | -$2.07M | SELL | -76.33% | 12.41K | Jun 20 - Jun 22 | View |
| Dec 02, 2022 | MERIDIAN VENTURE PARTNERS II LPMeridian Venture Partners II GP LPMeridian Venture Partners II CoRobert E. Brown Jr. | DIRECTOR | -200.00K | $38.50 | -$7.70M | SELL | -9.01% | 2.02M | Dec 01 | View |
| Aug 16, 2022 | James G Marken | SVP OPS & PROD DEV | -18.07K | $37.26 | -$673.07K | SELL | -13.31% | 117.64K | Aug 12 - Aug 15 | View |
| Mar 23, 2022 | Nikhil Lalwani | PRESIDENT & CEO | 7.22K | $27.69 | $200.00K | BUY | 4.45% | 169.65K | Mar 21 | View |
| Mar 22, 2022 | Patrick D Walsh | — | 5.00K | $27.76 | $138.79K | BUY | 10.33% | 53.39K | Mar 21 | View |
| Mar 22, 2022 | Chad Gassert | SVP - CORP. DEV. & STRATEGY | 10.00K | $27.51 | $275.09K | BUY | 2.61% | 393.23K | Mar 18 - Mar 21 | View |
| Mar 21, 2022 | Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS | 10.00K | $27.65 | $276.50K | BUY | 0.75% | 1.34M | Mar 17 | View |
| Dec 22, 2021 | Jeanne Thoma | — | 1.07K | $46.47 | $49.82K | BUY | 6.41% | 17.79K | Dec 20 | View |
| Dec 09, 2021 | Antonio R Pera | — | 3.00K | $42.26 | $126.79K | BUY | 17.95% | 19.71K | Dec 07 | View |
| Dec 07, 2021 | Thomas Haughey | — | 2.50K | $39.38 | $98.45K | BUY | 9.02% | 30.20K | Dec 06 | View |
| Mar 17, 2021 | Patrick D Walsh | — | 4.00K | $32.89 | $131.56K | BUY | 11.40% | 39.10K | Mar 15 | View |
| Nov 12, 2020 | Patrick D Walsh | — | 5.00K | $25.96 | $129.80K | PURCHASE | 16.61% | 35.10K | Nov 09 | View |
| Aug 12, 2020 | Patrick D Walsh | — | 10.00K | $30.78 | $307.79K | PURCHASE | 49.76% | 30.10K | Aug 10 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.